Abstract: The present invention pertains to a method for manufacturing a ready-to-use peptide emulsion on the industrial scale, comprising the step of emulsifying a suspension of at least two peptides under low shear conditions with at least one adjuvant. It is also directed to a ready-to-use emulsion obtainable according to this method. This invention allows the delivery of a scalable emulsion of peptides which preserves their integrity and fulfills the requirements needed for a pharmaceutical sterile product.

Abstract: The present invention pertains to a method for manufacturing a ready-to-use peptide emulsion on the industrial scale, comprising the step of emulsifying a suspension of at least two peptides under low shear conditions with at least one adjuvant. It is also directed to a ready-to-use emulsion obtainable according to this method. This invention allows the delivery of a scalable emulsion of peptides which preserves their integrity and fulfills the requirements needed for a pharmaceutical sterile product.

Abstract: The present invention relates to an inhibitor of the expression of IRS-1 for treating an angiogenic and/or inflammatory skin disease. The present invention also relates to a transdermal composition, preferably an ointment, comprising an inhibitor of the expression of IRS-1, and to the use thereof for treating an angiogenic and/or inflammatory skin disease.

Abstract: The present invention relates to an inhibitor of the expression of IRS-1 for treating an angiogenic and/or inflammatory skin disease. The present invention also relates to a transdermal composition, preferably an ointment, comprising an inhibitor of the expression of IRS-1, and to the use thereof for treating an angiogenic and/or inflammatory skin disease.

Abstract: The present invention relates to an inhibitor of the expression of IRS-1 for treating an angiogenic and/or inflammatory skin disease. The present invention also relates to a transdermal composition, preferably an ointment, comprising an inhibitor of the expression of IRS-1, and to the use thereof for treating an angiogenic and/or inflammatory skin disease.

Abstract: This invention relates to a pharmaceutical composition for the treatment and/or prevention of at least one pathological neovascularization-related conditions of the interior of the eye, the composition comprising a therapeutically effective amount of an antisens oligonucleotide having the sequence SEQ ID NO: 1: 5?-TCTCCGGAGGGCTCGCCATGCTGCT-3? or any function conservative sequence comprising from 9 to 30 nucleotides that has 75%, 80%, 85%, 90%, 95% or more than 95%, 96%, 97%, 98%, 99% of identity compared to SEQ ID NO: 1 and that conserves the capacity of inhibiting IRS-1 gene expression as SEQ ID NO: 1, and the composition being administered within the posterior segment of the eye to a subject in need thereof; this invention also relates to a method for treating a pathological neovascularization-related condition of the interior of the eye in a subject in need thereof comprising administering to the subject a therapeutically effective amount of said pharmaceutical composition.

Abstract: This invention relates to a pharmaceutical composition for the treatment and/or prevention of at least one pathological neovascularization-related conditions of the interior of the eye, the composition comprising a therapeutically effective amount of an antisense oligonucleotide having the sequence SEQ ID NO: 1: 5?-TCTCCGGAGGGCTCGCCATGCTGCT-3? or any function conservative sequence comprising from 9 to 30 nucleotides that has 75%, 80%, 85%, 90%, 95%, more than 95%, 96%, 97%, 98%, or 99% identity compared to SEQ ID NO: 1 and that conserves the capacity of inhibiting IRS-1 gene expression as SEQ ID NO: 1, and the composition being administered to a subject in need thereof, by intraocular route. This invention also relates to a method for treating a pathological neovascularization-related condition of the interior of the eye in a subject in need thereof comprising administering to the subject a therapeutically effective amount of the pharmaceutical composition.